review continu momentum
ta next-gen cro win
net dbt
sale estim adj ep beat street
revenu y/i cc rel recast
our/street driven technolog analyt
solut ta segment adj ebitda y/i margin
our/street estimate adj ep y/i
estimate higher interest expens street first look note link
addit detail
momentum ta next-gen revenu still come
overal think post good saw continu momentum ta
driven chiefli recent deal encourag posit data
point includ select iqv commerci technolog suit roch
solut ds expect sequenti deceler organ revenu
growth post last quarter due tougher prior-year comparison organ
bit light estimate weve note iqv data-
driven/next-gen solut contribut observ backlog busi win
momentum quarterli contract net book-to-bil recent
win translat revenu latter part model
 ds organ revenu growth acceler current level
ytd still shi high-singl digit number thought would
achiev base estim increment annual revenu growth rate
end year convey time quintiles-im merger
lastli base current fx trend guid revenu headwind
said stronger usd tailwind profit adj ebitda
ep given mix reiter buy rate share believ
recent win rate capit deploy help improv growth next year
adjust est fx interest exp rais po
model revenu rel prior estimate
fx adj ep rel prior estimate higher net interest
expens model revenu rel
prior estimate fx adj ep rel prior estimate rais po
still base adj ep estimate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
ia lead global provid
inform technolog solut contract
research servic compani world
largest cro contract research organ
largest sourc drug util data
focus use data advanc analyt
scienc help healthcar stakehold find better
solut patient compani
employe serv client
posit pharma biotech end
market remain healthi addit also
believ abl grow competit
leverag differenti next-gener
clinic develop offer commerci
technolog solut potenti growth
upsid capit deploy
price object base adj ep estim multipl
slight premium histor averag price-to-earnings think warrant
posit current cro industri trend risk price object lower
biopharma commerci spend custom consolid data suppli secur
risk competit technolog risk execut risk regulatori risk
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
